Reuters : Health (56)

Sanofi investors hungry for drug progress and deal news

PARIS - Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters.

'Heat-not-burn' tobacco may be safer but still a risk: UK panel

LONDON - A new wave of "heat-not-burn" tobacco products are probably safer than traditional cigarettes but the devices still produce a number of potentially harmful compounds, some of which are carcinogenic, a British panel of experts said on Tuesday.

EU health and food safety experts warn of stubborn salmonella

LONDON - The number of salmonella food poisoning cases in the European Union has risen by 3 percent since 2014 in a "worrying" reversal of a decade-long declining trend, EU health and food safety officials said on Tuesday.

Cholera resurges in Zambian capital Lusaka, WHO says

GENEVA - Cholera has killed 15 people and made 547 sick in Zambia's capital Lusaka and the rising caseload is expected to grow further as the rainy season starts, according to the World Health Organization.

FDA proposes new fast path to market for certain medical devices

- The U.S. Food and Drug Administration on Monday proposed creating a new fast track to market for certain medical devices and a potential reduction in the amount of safety data required for approval.

'Ground-breaking' new drug gives hope in Huntington's disease

LONDON - Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.

U.S. FDA accepts application for Indivior's new schizophrenia drug

- U.S. Food and Drug Administration accepted Indivior's application for its new schizophrenia treatment, the British drugmaker said on Tuesday, boosting hopes of marketing the drug in the country.

Promising responses seen with Agios leukemia drug in study

- Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.

Medical lab trade group sues over U.S. reimbursement cuts

- A U.S. trade association representing medical laboratories filed a lawsuit on Monday challenging a new reimbursement system used by the federal government that it said would reduce how much Medicare pays for labs by about $670 million in 2018.

Amgen's Kyprolis improves overall survival in blood cancer patients

- Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

Austria to drop impending smoking ban, bucking Western trend

VIENNA - While much of the West has barred smoking in restaurants and bars, Austria's impending ban is set to be stubbed out.

FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

- The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog.

NZ's Fisher & Paykel sues Resmed in Australia over patent dispute

- New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

Air pollution fine particles linked to poor sperm quality

- Exposure to fine particles in air pollution may be another factor that affects men's sperm quality and their fertility, suggest researchers in Taiwan.

GSK's new pharma head on lookout for cancer deals to boost pipeline

LONDON - GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its presence in oncology, its new head of pharmaceuticals told Reuters.

Roche: Tecentriq cocktail slows kidney cancer progression

ZURICH - Combining Roche's Tecentriq immunotherapy with its older drug Avastin for the initial treatment of advanced kidney cancer reduced the risk of the disease worsening or of death in certain patients, the Swiss drugmaker said on Monday.

'Ground-breaking' new drug gives hope on Huntingdon's disease

LONDON - Scientists have for the first time fixed a protein defect that causes Huntingdon's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.

Indonesia races to contain diphtheria outbreak ahead of 2018 Asian Games

JAKARTA - Health authorities in Jakarta kicked off a special immunization program on Monday to rein in an "extraordinary" outbreak of diphtheria that has sparked concerns about the Indonesian capital's readiness to host the Asian Games next June. Diphtheria cases have spiked 42 percent since last ...

Roche: Tecentriq cocktail slows kidney cancer progression

ZURICH - Combining Roche's Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death for the initial treatment of advanced kidney cancer in some patients, the Swiss drugmaker said on Monday

Merck raises stakes in lung cancer as rivals close in

LOS ANGELES - Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer.

Hospital operators in merger talks to form U.S. industry leader: WSJ

NEW YORK - Ascension Health and Providence St. Joseph Health are in talks about a merger between the two Catholic non-profits that would create the largest U.S. hospital chain, the Wall Street Journal reported on Sunday, citing people familiar with the discussions.

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

- More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

Novartis CAR-T therapy leads to durable response in lymphoma study

- Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a medical meeting on Sunday.

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

- More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday.

France orders international recall of Lactalis baby formula

PARIS - France has ordered banned the sale and ordered a recall of several baby formula milk and baby food products made by French dairy giant Lactalis after the discovery of salmonella bacteria, consumer protection agency DGCCRF said in a statement.

Roche lymphoma drug drives high remission rate, longer survival: study

- An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting ...

Pfizer breast cancer drug superior to chemotherapy in late stage study

- Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental Pfizer Inc drug went about three months longer before their disease worsened than those who received chemotherapy in a late stage study, according to data released on Friday.

U.S. Department of Justice investigating fetal tissue transfers

- The U.S. Department of Justice asked on Thursday for documents related to a Senate committee's report on the transfer of fetal tissue by abortion provider Planned Parenthood, according to a letter seen by Reuters.

Roche study finds cancer 'Velcro' that halts T-cell attack

ZURICH - Scientists at Swiss drugmaker Roche said on Friday they may have discovered why some tumors resist new immunotherapy drugs as well as a possible means of turning the tables to incite a T-cell attack.

Philippines to seek refund of $59 million from Sanofi amid vaccine risk

MANILA - The Philippines will seek the return of 3 billion pesos it paid French drugmaker Sanofi for a dengue vaccine used to immunize hundreds of thousands of children that Sanofi has said could worsen the disease in some cases.

Antibiotics sales for use in U.S. farm animals dropped in 2016: FDA

CHICAGO - The sale and distribution of antibiotics approved for use in food-producing animals in the United States decreased by 10 percent from 2015 to 2016, a U.S. Food and Drug Administration report said on Thursday.

More than 2,000 drugs now in cancer immunotherapy race

LONDON - The race to develop new immunotherapy treatments against cancer has sparked an unprecedented explosion in the oncology drug pipeline, with more than 2,000 immune system-boosting agents now in development.

Roche drug cocktail doubles chance of holding lung cancer at bay

ZURICH - Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented.

Childhood cancer survivors have more blood pressure problems

- More than one in 12 adult survivors of childhood cancers may have undiagnosed high blood pressure, a U.S. study suggests.

Faulty positioning in rugby tackles boosts injury risk

- Head, neck and shoulder injuries during rugby tackles are more common when the tackler's head is incorrectly positioned in relation to the ball carrier, a small study has found.

Roche drug cocktail doubles chance of holding lung cancer at bay

ZURICH - Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labeled unprecedented.

Indonesia fights 'extraordinary' diphtheria outbreak that has killed 32

JAKARTA - Indonesian health authorities will launch an immunization drive next week to contain a sharp rise in cases of diphtheria, which has killed at least 32 people, including many children, in the world's fourth most populous country this year.

Sage shares surge as depression drug succeeds mid-stage trial

- Sage Therapeutics Inc's shares surged more than 63 percent premarket on Thursday, on track to add about $2.5 billion to the company's market value, after its drug succeeded in reducing the symptoms of depression in a mid-stage trial.

Roche to seize leap-frog opportunity in lung cancer

LONDON - After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer.

UnitedHealth to buy DaVita primary care unit for $4.9 billion

- The largest U.S. health insurer UnitedHealth Group Inc will buy DaVita Inc's primary and urgent care services for $4.9 billion in its second acquisition this year to expand its fast-growing medical group, it said on Wednesday.

Roche drug cocktail doubles chance of holding lung cancer at bay

ZURICH - Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labelled unprecedented.

U.S. healthcare spending growth slowed in 2016

- Growth in healthcare spending in the United States slowed in 2016 following two years of expansion under the Affordable Care Act, a government health agency reported on Wednesday.

Kids aren't protecting themselves against STDs during oral sex

- Adolescents and young adults regularly engage in oral sex but seldom use condoms to prevent the spread of sexually transmitted diseases, new research shows.

FDA proposes drug development guidance for rare pediatric diseases

- The U.S. Food and Drug Administration issued a draft guidance on Wednesday to simplify the procedure of developing drugs for rare pediatric disorders, such as Gaucher's disease, by eliminating the need for certain trials and minimizing patient enrollment.

Knee surgery outcomes linked with education level

- Patients who live in low-income communities and lack a college education may have worse pain after knee replacement surgery than their more educated neighbors, a recent study suggests.

High tech, high finance and high times for U.S. pot industry

- Two years ago, Alan Gertner was head of Google's Asia-Pacific sales team in Singapore, handling more than $100 million in business.

UnitedHealth to buy DaVita primary care unit for $4.9 billion

- U.S. health insurer UnitedHealth Group Inc on Wednesday announced a $4.9 billion deal to buy a unit of DaVita Inc, looking to bolster its primary and urgent care services.

GSK, other drugmakers bet on post-Brexit UK science

LONDON - Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit.

Myanmar's opium crop plummets, but no victory over Asia's narco-boom: U.N.

BANGKOK - A "dramatic" drop in opium cultivation in Myanmar underscored a regional boom in demand for illegal synthetic drugs such as methamphetamine, which many Asian countries are struggling to combat, a senior U.N. official said on Wednesday.

FDA approves Novo Nordisk diabetes drug Ozempic

- The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.